---
title: "Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285754776.md"
description: "Incyte (INCY) is conducting a Phase 3 trial, DAWN-303, to evaluate the efficacy of its oral drug INCB161734 in combination with standard chemotherapy for patients with KRAS G12D-mutated metastatic pancreatic cancer. The trial aims to determine if this combination improves treatment outcomes compared to chemotherapy alone. The study is randomized and double-blind, currently active in recruitment. This initiative marks Incyte's expansion into targeted solid tumors, potentially enhancing its market position in oncology. Further updates can be found on ClinicalTrials.gov."
datetime: "2026-05-08T16:34:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285754776.md)
  - [en](https://longbridge.com/en/news/285754776.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285754776.md)
---

# Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

Incyte (INCY) announced an update on their ongoing clinical study.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Incyte Inc. (INCY) is running a phase 3 trial called DAWN-303 to test chemotherapy with or without its oral drug INCB161734 in patients with KRAS G12D-mutated metastatic pancreatic cancer. The goal is to see if adding this new pill to current standard care improves outcomes in a hard-to-treat cancer and could open a niche, mutation-focused market.

The trial compares INCB161734 plus standard chemo against a placebo pill plus the same chemo. INCB161734 is an oral tablet designed to work alongside mFOLFIRINOX or GemNabP, two common chemo options, to boost treatment effect without changing the core regimen doctors already know.

This is a randomized study, so patients are assigned by chance to either the active drug or placebo group. It is double-blind, meaning neither patients nor doctors know who gets the real drug, and the primary aim is to test how well the treatment works and how safe it is compared with chemo alone.

The study was first submitted on April 3, 2026, which signals when the trial formally entered the public registry. The last update was filed on May 7, 2026, showing that the record is current and that the recruiting status remains active as the study moves through early enrollment.

For investors, this update underscores Incyte’s push into targeted solid tumors beyond its core hematology base. Success could support a new growth leg in oncology, sharpen its profile versus peers working on KRAS pathways, and, if data are strong, lift sentiment and valuation, though timelines and trial risk remain key factors.

The DAWN-303 study is currently recruiting and remains active, with further details and ongoing updates available on the ClinicalTrials.gov portal for NCT07522073.

To learn more about INCY’s potential, visit the Incyte drug pipeline page.

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [SMC backs first-line metastatic bladder cancer combination after trial results](https://longbridge.com/en/news/286065296.md)
- [MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results](https://longbridge.com/en/news/286319406.md)
- [Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator](https://longbridge.com/en/news/286309051.md)
- [Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial](https://longbridge.com/en/news/286042283.md)
- [Canada's Knight Therapeutics Q1 revenue jumps 69%, beats estimates](https://longbridge.com/en/news/285531982.md)